Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.15 Insider Own19.99% Shs Outstand4.44M Perf Week-10.42%
Market Cap5.73M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.55M Perf Month-4.44%
Income-5.00M PEG- EPS next Q- Inst Own7.96% Short Float0.32% Perf Quarter50.00%
Sales0.00M P/S- EPS this Y- Inst Trans-1.71% Short Ratio1.07 Perf Half Y60.25%
Book/sh0.83 P/B1.56 EPS next Y- ROA-80.91% Short Interest0.01M Perf Year-33.85%
Cash/sh0.91 P/C1.41 EPS next 5Y- ROE-94.48% 52W Range0.68 - 2.32 Perf YTD30.30%
Dividend Est.- P/FCF- EPS past 5Y-2.91% ROI-136.32% 52W High-44.40% Beta-
Dividend TTM- Quick Ratio6.41 Sales past 5Y0.00% Gross Margin- 52W Low89.79% ATR (14)0.17
Dividend Ex-Date- Current Ratio6.41 EPS Y/Y TTM-39.72% Oper. Margin0.00% RSI (14)41.22 Volatility11.06% 13.01%
Employees3 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price16.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-175.07% Payout- Rel Volume0.40 Prev Close1.37
Sales Surprise- EPS Surprise37.50% Sales Q/Q- EarningsApr 01 AMC Avg Volume10.63K Price1.29
SMA20-18.47% SMA503.17% SMA200-2.80% Trades Volume4,290 Change-5.84%
Apr-17-24 08:42AM
Apr-01-24 09:53PM
Mar-27-24 08:42AM
Mar-25-24 05:00PM
08:41AM Loading…
Mar-21-24 08:41AM
Feb-13-24 08:30AM
Dec-12-23 07:30AM
Oct-13-23 09:00AM
Sep-26-23 08:18AM
Mar-22-23 12:55PM
Apr-26-22 08:15AM
Nov-16-21 09:58AM
Aug-30-21 09:15AM
Aug-17-21 07:45AM
04:21PM Loading…
Jul-23-21 04:21PM
Jul-08-21 11:20AM
Jul-06-21 06:17AM
Jun-23-21 09:35AM
Jun-16-21 09:15AM
Apr-29-21 03:06PM
Apr-26-21 08:58PM
Dec-16-20 09:15AM
Sep-08-20 12:10PM
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arrow Alexander K.Chief Financial OfficerOct 12 '23Buy0.818,0006,48045,815Oct 13 12:48 PM